Abstract
The relationship between prognosis and tumor marker (TM) value fluctuation during treatment has only been reported in patients with resectable or stage IV non-small cell lung cancer (NSCLC). This study focused on patients with stage III NSCLC who received chemoradiotherapy (CRT).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
